by Allen Koester, Will Knapp, and Anderson Kong
Pharmaceutical companies operate in one of the most energy-intensive sectors, driven by complex production processes, stringent regulatory requirements, and the need for precise environmental controls to maintain product integrity. These demands make decarbonization particularly challenging, yet the industry is increasingly committed to reducing its carbon footprint.
Key Areas for Decarbonization in Pharmaceutical Manufacturing
Several focus areas offer significant potential for impactful, scalable carbon reduction:
Alternative Heating Technologies
Non-fossil fuel heating options such as electric boilers, heat pumps, geothermal systems, and hydrogen-based systems are being adopted to lower emissions. These technologies offer varying levels of efficiency and suitability depending on a facility’s location, climate, and infrastructure.
Air Recirculation
Pharmaceutical facilities traditionally use significant outdoor air to meet strict environmental standards, but conditioning this air is energy-intensive. New approaches that optimize air recirculation reduce energy use without compromising air quality. Clean rooms, for instance, can maintain high standards with reduced air change rates if designed with advanced filtration and control systems, offering substantial energy savings.
Control Systems
Modern control systems play a pivotal role in decarbonization by automating and optimizing the operation of critical equipment such as HVAC systems, chiller plants, and compressed air systems. By continuously monitoring and adjusting operations based on real-time needs, these systems minimize energy waste. For example, adjusting chiller set points or turning off idle compressors can lead to significant energy reductions.
Central Plant and Manufacturing Process Improvements
By upgrading aging equipment and implementing heat recovery systems, companies can reduce the energy used for key functions such as steam generation and water purification. This not only cuts emissions but also lowers operational costs over time.
Reducing Fossil Fuel-burning Equipment
Electrification of equipment, particularly boilers, is a major focus for decarbonization. Shifting from traditional gas-fired boilers to electric or hybrid alternatives leads to immediate reductions in emissions. Although this transition requires significant capital investment, it offers a clear pathway toward long-term sustainability.
On-site Renewable Energy Generation
Installing solar panels, wind turbines, or geothermal systems allows facilities to generate renewable energy on-site, reducing their reliance on fossil fuels. Additionally, many pharmaceutical companies are entering into power purchase agreements (PPAs) to source renewable energy from external providers, further decreasing their carbon footprint. These strategies ensure a stable supply of clean energy, even in energy-intensive operations.
Practical Insights for Achieving Decarbonization Goals
Meeting decarbonization targets can seem overwhelming, but these insights can help guide companies toward meaningful progress:
Measure to Improve
Start by establishing a baseline for carbon emissions, then track energy use, emissions, and waste streams with the help of sensors, meters, and data analytics. This data-driven approach allows for the identification of inefficiencies and highlights areas where emissions can be reduced most effectively.
Focus on Incremental Progress
Breaking ambitious sustainability targets into smaller, achievable milestones makes the process more manageable. Incremental improvements allow companies to build momentum, celebrate success, and adapt strategies as needed. The small projects and wins will also bring credibility to the high level CapEx leaders, thus increasing the size of projects further down the road.
Learn from Others
Collaborating with peers and industry associations like the International Society for Pharmaceutical Engineering (ISPE) can accelerate decarbonization efforts. These networks offer valuable insights into emerging technologies, regulatory trends, and successful strategies used by other companies.
Partner with Experts
Consulting with firms that specialize in decarbonization, particularly within the pharmaceutical sector, can streamline the process. These experts can provide tailored strategies that align with both regulatory requirements and operational goals, helping companies reduce emissions while maximizing efficiency.
Whether you’re just beginning or enhancing ongoing sustainability efforts, the decarbonization of pharmaceutical manufacturing is both a business and environmental imperative. Taking steps to reduce emissions not only aligns with global sustainability goals but can also strengthen your company’s operational resilience and reputation.
Allen Koester, PE, PMP is senior vice president, Will Knapp is a director of pharmaceutical projects, and Anderson Kong, P.Eng, LEED AP is a principal, at Salas O’Brien.
